Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital boosted their Q2 2025 earnings estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, May 6th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.21) per share for the quarter, up from their previous estimate of ($0.26). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.46 EPS and FY2029 earnings at $3.39 EPS.
Several other brokerages have also commented on NVCT. HC Wainwright restated a "buy" rating and set a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a research note on Wednesday, April 30th. Maxim Group assumed coverage on shares of Nuvectis Pharma in a research report on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price target on the stock. Finally, Laidlaw assumed coverage on shares of Nuvectis Pharma in a research report on Monday, March 17th. They set a "buy" rating and a $19.00 price target for the company.
Check Out Our Latest Report on Nuvectis Pharma
Nuvectis Pharma Stock Performance
Shares of NASDAQ:NVCT traded up $0.61 during mid-day trading on Friday, hitting $9.04. The stock had a trading volume of 86,179 shares, compared to its average volume of 127,026. Nuvectis Pharma has a 12-month low of $4.44 and a 12-month high of $11.80. The company's 50 day moving average is $9.03 and its 200-day moving average is $7.20. The company has a market cap of $213.66 million, a PE ratio of -7.79 and a beta of -0.11.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.03.
Insiders Place Their Bets
In other news, major shareholder Marlio Charles Mosseri bought 12,444 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were bought at an average price of $8.59 per share, with a total value of $106,893.96. Following the completion of the transaction, the insider now owns 2,896,565 shares of the company's stock, valued at $24,881,493.35. This trade represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders bought 36,261 shares of company stock worth $301,481. Corporate insiders own 35.78% of the company's stock.
Institutional Investors Weigh In On Nuvectis Pharma
Several institutional investors have recently made changes to their positions in the stock. Baldwin Wealth Partners LLC MA increased its position in Nuvectis Pharma by 0.7% in the 1st quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock valued at $3,502,000 after acquiring an additional 2,500 shares during the period. Iridian Asset Management LLC CT bought a new position in shares of Nuvectis Pharma in the first quarter valued at approximately $2,481,000. Marshall Wace LLP increased its stake in Nuvectis Pharma by 191.0% in the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after acquiring an additional 81,757 shares during the last quarter. Geode Capital Management LLC lifted its position in Nuvectis Pharma by 49.8% in the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company's stock worth $501,000 after buying an additional 26,489 shares during the last quarter. Finally, Forbes J M & Co. LLP boosted its stake in shares of Nuvectis Pharma by 21.9% during the fourth quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company's stock valued at $319,000 after purchasing an additional 10,599 shares during the period. 96.77% of the stock is currently owned by institutional investors.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Further Reading
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
